vs
VICOR CORP（VICR）与Varex Imaging Corp（VREX）财务数据对比。点击上方公司名可切换其他公司
Varex Imaging Corp的季度营收约是VICOR CORP的1.9倍（$209.6M vs $113.0M）。VICOR CORP净利率更高（18.3% vs 1.1%，领先17.2%）。VICOR CORP同比增速更快（20.2% vs 4.9%）。过去两年VICOR CORP的营收复合增速更高（14.7% vs 0.8%）
Vicor Corporation是总部位于美国马萨诸塞州安多弗的电源模块专业制造商，深耕高性能电源模块的研发、生产与销售，可为多个行业客户提供高效可靠的电源解决方案，在全球电源技术领域具备较强的技术优势与市场竞争力。
Varex Imaging是全球知名的影像组件及解决方案供应商，核心产品涵盖X射线管、数字平板探测器和图像处理软件，广泛应用于医疗诊断、放射肿瘤治疗及工业无损检测等领域，客户覆盖全球主要市场。
VICR vs VREX — 直观对比
营收规模更大
VREX
是对方的1.9倍
$113.0M
营收增速更快
VICR
高出15.3%
4.9%
净利率更高
VICR
高出17.2%
1.1%
两年增速更快
VICR
近两年复合增速
0.8%
损益表 — Q1 2026 vs Q1 2026
| 指标 | | |
|---|---|---|
| 营收 | $113.0M | $209.6M |
| 净利润 | $20.7M | $2.3M |
| 毛利率 | — | 33.3% |
| 营业利润率 | — | 7.3% |
| 净利率 | 18.3% | 1.1% |
| 营收同比 | 20.2% | 4.9% |
| 净利润同比 | 713.9% | 866.7% |
| 每股收益（稀释后） | $0.44 | $0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收VICRVREX
| Q1 26 | $113.0M | $209.6M | ||
| Q4 25 | $107.3M | $228.9M | ||
| Q3 25 | $110.4M | $203.0M | ||
| Q2 25 | $96.0M | $212.9M | ||
| Q1 25 | $94.0M | $199.8M | ||
| Q4 24 | $96.2M | — | ||
| Q3 24 | $93.2M | $205.7M | ||
| Q2 24 | $85.9M | $209.1M |
净利润VICRVREX
| Q1 26 | $20.7M | $2.3M | ||
| Q4 25 | $46.5M | $12.2M | ||
| Q3 25 | $28.3M | $-89.1M | ||
| Q2 25 | $41.2M | $6.9M | ||
| Q1 25 | $2.5M | $-300.0K | ||
| Q4 24 | $10.2M | — | ||
| Q3 24 | $11.6M | $-51.1M | ||
| Q2 24 | $-1.2M | $1.4M |
毛利率VICRVREX
| Q1 26 | — | 33.3% | ||
| Q4 25 | 55.4% | 34.0% | ||
| Q3 25 | 57.5% | 33.3% | ||
| Q2 25 | 95.9% | 36.0% | ||
| Q1 25 | 47.2% | 34.3% | ||
| Q4 24 | 52.4% | — | ||
| Q3 24 | 49.1% | 32.6% | ||
| Q2 24 | 49.8% | 32.0% |
营业利润率VICRVREX
| Q1 26 | — | 7.3% | ||
| Q4 25 | 14.6% | 8.6% | ||
| Q3 25 | 18.9% | -39.8% | ||
| Q2 25 | 47.3% | 10.4% | ||
| Q1 25 | -0.2% | 5.6% | ||
| Q4 24 | 9.6% | — | ||
| Q3 24 | 5.8% | 5.3% | ||
| Q2 24 | 0.2% | 4.4% |
净利率VICRVREX
| Q1 26 | 18.3% | 1.1% | ||
| Q4 25 | 43.4% | 5.3% | ||
| Q3 25 | 25.6% | -43.9% | ||
| Q2 25 | 42.9% | 3.2% | ||
| Q1 25 | 2.7% | -0.2% | ||
| Q4 24 | 10.7% | — | ||
| Q3 24 | 12.4% | -24.8% | ||
| Q2 24 | -1.4% | 0.7% |
每股收益（稀释后）VICRVREX
| Q1 26 | $0.44 | $0.05 | ||
| Q4 25 | $1.01 | $0.29 | ||
| Q3 25 | $0.63 | $-2.15 | ||
| Q2 25 | $0.91 | $0.17 | ||
| Q1 25 | $0.06 | $-0.01 | ||
| Q4 24 | $0.24 | — | ||
| Q3 24 | $0.26 | $-1.25 | ||
| Q2 24 | $-0.03 | $0.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $404.2M | $125.6M |
| 总债务越低越好 | — | $367.6M |
| 股东权益账面价值 | $754.1M | $476.9M |
| 总资产 | $804.9M | $1.1B |
| 负债/权益比越低杠杆越低 | — | 0.77× |
8季度趋势，按日历期对齐
现金及短期投资VICRVREX
| Q1 26 | $404.2M | $125.6M | ||
| Q4 25 | $402.8M | $155.1M | ||
| Q3 25 | $362.4M | $152.6M | ||
| Q2 25 | $338.5M | $223.0M | ||
| Q1 25 | $296.1M | $212.6M | ||
| Q4 24 | $277.3M | — | ||
| Q3 24 | $267.6M | $200.5M | ||
| Q2 24 | $251.9M | $190.0M |
总债务VICRVREX
| Q1 26 | — | $367.6M | ||
| Q4 25 | — | $367.5M | ||
| Q3 25 | — | $367.5M | ||
| Q2 25 | — | $567.2M | ||
| Q1 25 | — | $567.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $443.4M | ||
| Q2 24 | — | $443.1M |
股东权益VICRVREX
| Q1 26 | $754.1M | $476.9M | ||
| Q4 25 | $711.6M | $472.6M | ||
| Q3 25 | $630.1M | $455.3M | ||
| Q2 25 | $608.6M | $549.7M | ||
| Q1 25 | $580.3M | $540.2M | ||
| Q4 24 | $570.1M | — | ||
| Q3 24 | $554.6M | $529.1M | ||
| Q2 24 | $537.2M | $581.2M |
总资产VICRVREX
| Q1 26 | $804.9M | $1.1B | ||
| Q4 25 | $785.8M | $1.1B | ||
| Q3 25 | $710.2M | $1.1B | ||
| Q2 25 | $693.5M | $1.4B | ||
| Q1 25 | $665.0M | $1.3B | ||
| Q4 24 | $641.1M | — | ||
| Q3 24 | $632.8M | $1.2B | ||
| Q2 24 | $613.2M | $1.3B |
负债/权益比VICRVREX
| Q1 26 | — | 0.77× | ||
| Q4 25 | — | 0.78× | ||
| Q3 25 | — | 0.81× | ||
| Q2 25 | — | 1.03× | ||
| Q1 25 | — | 1.05× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.84× | ||
| Q2 24 | — | 0.76× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-16.1M |
| 自由现金流经营现金流 - 资本支出 | — | $-26.8M |
| 自由现金流率自由现金流/营收 | — | -12.8% |
| 资本支出强度资本支出/营收 | — | 5.1% |
| 现金转化率经营现金流/净利润 | — | -7.00× |
| 过去12个月自由现金流最近4个季度 | — | $-13.3M |
8季度趋势，按日历期对齐
经营现金流VICRVREX
| Q1 26 | — | $-16.1M | ||
| Q4 25 | $15.7M | $7.9M | ||
| Q3 25 | $38.5M | $7.7M | ||
| Q2 25 | $65.2M | $16.6M | ||
| Q1 25 | $20.1M | $9.5M | ||
| Q4 24 | $10.1M | — | ||
| Q3 24 | $22.6M | $25.9M | ||
| Q2 24 | $15.6M | $8.0M |
自由现金流VICRVREX
| Q1 26 | — | $-26.8M | ||
| Q4 25 | $10.2M | $2.3M | ||
| Q3 25 | $34.5M | $1.4M | ||
| Q2 25 | $59.0M | $9.8M | ||
| Q1 25 | $15.6M | $5.3M | ||
| Q4 24 | $8.4M | — | ||
| Q3 24 | $14.1M | $19.9M | ||
| Q2 24 | $9.4M | $3.3M |
自由现金流率VICRVREX
| Q1 26 | — | -12.8% | ||
| Q4 25 | 9.5% | 1.0% | ||
| Q3 25 | 31.2% | 0.7% | ||
| Q2 25 | 61.5% | 4.6% | ||
| Q1 25 | 16.6% | 2.7% | ||
| Q4 24 | 8.7% | — | ||
| Q3 24 | 15.2% | 9.7% | ||
| Q2 24 | 11.0% | 1.6% |
资本支出强度VICRVREX
| Q1 26 | — | 5.1% | ||
| Q4 25 | 5.2% | 2.4% | ||
| Q3 25 | 3.6% | 3.1% | ||
| Q2 25 | 6.5% | 3.2% | ||
| Q1 25 | 4.8% | 2.1% | ||
| Q4 24 | 1.8% | — | ||
| Q3 24 | 9.1% | 2.9% | ||
| Q2 24 | 7.2% | 2.2% |
现金转化率VICRVREX
| Q1 26 | — | -7.00× | ||
| Q4 25 | 0.34× | 0.65× | ||
| Q3 25 | 1.36× | — | ||
| Q2 25 | 1.58× | 2.41× | ||
| Q1 25 | 7.93× | — | ||
| Q4 24 | 0.99× | — | ||
| Q3 24 | 1.95× | — | ||
| Q2 24 | — | 5.71× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
VICR
| Product revenue | $98.0M | 87% |
| Royalty revenue | $15.0M | 13% |
VREX
| Medical Segment | $144.8M | 69% |
| Industrial Segment | $64.8M | 31% |
